Prognostic factor of lenvatinib for unresectable hepatocellular carcinoma in real‐world conditions—Multicenter analysis

2019158 citationsJournal Articlegold Open Access

Authors

Atsushi Hiraoka · Ehime Prefectural Central Hospital

Takashi Kumada · Ogaki Municipal Hospital

Masanori Atsukawa · Nippon Medical School

Masashi Hirooka · Ehime University

Kunihiko Tsuji · Teine Keijinkai Hospital

Toru Ishikawa · Saiseikai Niigata Daini Hospital

Koichi Takaguchi

Abstract

Good hepatic function (mALBI 1/2a) is the best indication for LEN, while potential appetite loss in association with low BMI should be kept in mind in such cases.

Topics & Keywords

Hepatocellular Carcinoma Treatment and Prognosis Liver Disease Diagnosis and Treatment Liver physiology and pathology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Medicine

Volume 8, Issue 8, pp. 3719-3728

DOI: 10.1002/cam4.2241

Field-Weighted Citation Impact: 17.11